Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 8140 results

  1. Harmful gambling: identification, assessment and management

    In development [GID-NG10210] Expected publication date: 16 July 2024

    NICE guideline
    In development

  2. Avapritinib for treating advanced systemic mastocytosis ID3770

    In development [GID-TA11382] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. News

    Home testing devices could increase the number of people diagnosed with sleep condition Five home-testing devices to diagnose a silent

  4. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  5. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]

    In development [GID-TA10813] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]

    In development [GID-TA11390] Expected publication date: 24 July 2024

    Technology appraisal guidance
    In development

  7. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Mirikizumab for treating moderately to severely active Crohn's disease ID6244

    In development [GID-TA11267] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 5 June 2024.

    Diagnostics guidance
    In consultation

  10. Older people

    All NICE products on older people. Includes any guidance, advice and quality standards.

    Topic page

  11. Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]

    In development [GID-TA10615] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment

    In development [GID-HTE10030] Expected publication date: 15 August 2024

    Health technology evaluations
    In development

  13. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    Awaiting development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development